Quickly Identify more Options for Personalized Cancer Treatments
Move beyond Standard of Care with our Rapid Therapy Selection™ test to identify FDA-approved drug options with the best potential to treat each patient’s unique cancer.
Predictive Accuracy
In early studies, our innovative test matched the actual responses of 80% of treatments. Our predictive accuracy is being validated in multiple clinical trials.
Results in 2 days
We’ll deliver a test report two days after your patient’s sample collection. That’s the industry’s fastest turnaround time for cancer therapy guidance.
100+ Drugs to Test
Our lab tests a growing number of FDA-approved drugs on live tumor cells. You define a panel of up to 20 drugs per order to test.
Improve Therapy Selection
With Travera’s Rapid Therapy Selection™ test, you have a revolutionary tool to identify additional treatments for your cancer patients. We are moving cancer therapy beyond Standard of Care with innovative and proprietary technology developed at the Massachusetts Institute of Technology (MIT).
Our test weighs individual cancer cells ex vivo with sub-picogram accuracy. Weight change begins very quickly, within a few hours of exposing the cancer cells to effective cancer drugs, and it applies to many different cancer drugs with different mechanisms of action.
In an unprecedented two-day turnaround time, you can explore alternatives for patients who have run out of options.
Support Patients With New Alternatives
While the FDA has approved many drugs to treat specific cancers, every cancer patient’s cells are unique. Late-stage cancer patients may not have the time or endurance to test multiple drugs in vivo.
You can have a panel of up to 20 FDA-approved drugs tested per order. The test results will help determine which drugs or drug combinations have the potential to disrupt the growth of your patient’s cancer cells.
Specifically, use cases include:
Improve clinical decision-making with a list of the most viable alternatives for treating your patient’s unique cancer.
Identify drugs that will be ineffective and drop them from combination therapies.
Choose alternatives that are less toxic, and possibly less expensive, without compromising on efficacy.
Travera’s catalog includes over 100 drugs that can be tested against 90% of cancers.